Abstract

BackgroundIdentifying genetic predictors of methotrexate (MTX) therapy response in patients with rheumatoid arthritis (RA) may have importance for clinical benefit optimalization. MTX therapeutic effect is achieved by inhibiting enzymes of...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Identification of SNPs associated with methotrexate treatment outcomes in patients with early rheumatoid arthritis.
Manuela Zucknick ... Espen A Haavardsholm
Frontiers in pharmacology | VOL. 13
Manuela Zucknick, et. al.Manuela Zucknick ... Espen A Haavardsholm
17 Nov 2022
Presence of the methylenetetrahydrofolate reductase gene polymorphism MTHFR C677T in molar tissue but not maternal blood predicts failure of methotrexate treatment for low-risk gestational trophoblastic neoplasia
Hirokazu Usui ... Hiroshi Kaku
European Journal of Pharmacology | VOL. 794
Hirokazu Usui, et. al.Hirokazu Usui ... Hiroshi Kaku
11 Nov 2016
Predictive value of hemoperitoneum for outcome of methotrexate treatment in ectopic pregnancy: an observational comparative study
A Gnisci ... L Stefani
Ultrasound in Obstetrics & Gynecology | VOL. 43
A Gnisci, et. al.A Gnisci ... L Stefani
08 May 2014
Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent‐onset rheumatoid arthritis
Peter De Sonnaville ... Jan Lindemans
Arthritis & Rheumatism | VOL. 54
Peter De Sonnaville, et. al.Peter De Sonnaville ... Jan Lindemans
31 Aug 2006
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers